Ep 39 Suzetrigine in Acute Pain: Mechanism, Clinical Use, and What Comes Next

Suzetrigine, an FDA-approved medication for moderate to severe acute pain, offers a novel approach to pain management by selectively inhibiting peripheral NAV 1.8 sodium channels. Unlike traditional opioids or centrally acting analgesics, this mechanism avoids common side effects such as sedation, nausea, and constipation by bypassing the central nervous system. While currently utilized in perioperative settings, the drug’s clinical utility remains under evaluation, particularly regarding its efficacy in opioid-tolerant patients and chronic conditions like diabetic peripheral neuropathy. The development of this medication represents a significant shift in pain medicine, marking the first new class of therapeutic agents in nearly three decades. Future research aims to explore broader applications and potential combinations with other sodium channel-targeting therapies to enhance patient outcomes while minimizing reliance on conventional, higher-risk pain medications.